Close Menu
The Business TimesThe Business Times
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
What's On

Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript

16 November 2026

Vitalhub: Digesting Acquisitions While Preparing For More (TSX:VHI:CA)

16 November 2026

NioCorp: A Speculative Buy On The Development Of Domestic U.S. Critical Mineral Supply

16 November 2026

SPX Technologies, Inc. (SPXC) Presents at Baird 2026 Global Industrial Conference 2026 Transcript

16 November 2026

Northland Power: From Construction Cycle To Cash Flow Compounder (NPI:CA)

16 November 2026
Facebook X (Twitter) Instagram
Business Monday, Nov 16
The Business TimesThe Business Times
Newsletter
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
The Business TimesThe Business Times
Home » Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
News

Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript

thebusinesstimes.co.ukBy thebusinesstimes.co.uk16 November 20261 Views
Facebook Twitter LinkedIn Reddit Telegram WhatsApp Pinterest Tumblr VKontakte Email
Share
Facebook Twitter LinkedIn Pinterest Email

Ashwani Verma
UBS Investment Bank, Research Division

Great. Good day, everybody. My name is Ash Verma. I cover SMID-Cap Biotech and Spec Pharma at UBS and really excited to have Dianthus’ Marino Garcia, who’s the CEO. Thank you so much for joining us. Very excited to learn more about Dianthus today. I know you have some slides that you want to run through, and then we can get into some Q&A.

Marino Garcia
President, CEO & Director

Thank you, Ash, and thank you to UBS for this opportunity to update everyone on all the exciting developments at Dianthus Therapeutics. I’ll just take a few moments for — to set the stage, and then we can jump into the questions. Just obviously, I’ll be making some forward-looking statements. I just refer everyone to our website and our SEC filings for all the appropriate risks around Dianthus and investing in the company.

Before I jump into our lead program and set the stage for claseprubart, Dianthus, what we’re trying to do is build a very exciting autoimmune-focused biotech company. We have 3 programs. Our lead program, claseprubart, is a highly potent extended half-life active C1s inhibitor that inhibits only the classical pathway, leaving the lectin and alternative pathways intact. We’ll talk a little bit about what that means in terms of its differentiation.

Our second program is DNTH212. It’s a bifunctional fusion protein that we in-licensed from China last year. On one side, it’s a BDCA2 inhibitor that has demonstrated superior pDC depletion when compared to litifilimab, which is in Biogen’s portfolio, and we’ll be reading out two Phase III

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related Articles

Vitalhub: Digesting Acquisitions While Preparing For More (TSX:VHI:CA)

NioCorp: A Speculative Buy On The Development Of Domestic U.S. Critical Mineral Supply

SPX Technologies, Inc. (SPXC) Presents at Baird 2026 Global Industrial Conference 2026 Transcript

Northland Power: From Construction Cycle To Cash Flow Compounder (NPI:CA)

Voya GNMA Income Fund Q3 2026 Commentary

Wall Street Brunch: Nvidia, Anthropic And GTA 6 (undefined:NVDA)

EOS: An Attractive Tech-Focused Income Fund With Nearly 10% Yield (NYSE:EOS)

Imperial Brands: Massive Cash Flow Driving Double-Digit Returns (OTCMKTS:IMBBY)

ArriVent BioPharma: ARR-217 Gives Us A Reason To Reconsider Our Strong Sell

Editors Picks

Vitalhub: Digesting Acquisitions While Preparing For More (TSX:VHI:CA)

16 November 2026

NioCorp: A Speculative Buy On The Development Of Domestic U.S. Critical Mineral Supply

16 November 2026

SPX Technologies, Inc. (SPXC) Presents at Baird 2026 Global Industrial Conference 2026 Transcript

16 November 2026

Northland Power: From Construction Cycle To Cash Flow Compounder (NPI:CA)

16 November 2026

Subscribe to News

Get the latest finance and business news and updates directly to your inbox.

Latest Posts

Voya GNMA Income Fund Q3 2026 Commentary

15 November 2026

Wall Street Brunch: Nvidia, Anthropic And GTA 6 (undefined:NVDA)

15 November 2026

EOS: An Attractive Tech-Focused Income Fund With Nearly 10% Yield (NYSE:EOS)

15 November 2026
Facebook X (Twitter) Pinterest WhatsApp TikTok Instagram
© 2026 The Business Times. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.